Asia Pacific Diabetic Retinopathy Market Research Report - Segmented By Treatment Type, Indication, End User, By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 878
Pages: 142

APAC Diabetic Retinopathy Market Size (2023 to 2028)

The size of the diabetic retinopathy market in the Asia Pacific was valued at USD 1.80 billion in 2023 and is projected to reach USD 2.64 billion by 2028, growing at a CAGR of 7.94% during the forecast period.

Asia is predicted to show wealthy growth in the forecast period. Within the Asian region, the western pacific region accounts for a larger share of blindness due to DR when equated to South-East Asia. The primary factor contributing to the increasing share of Diabetic Retinopathy among the growing economies is a vast pool of patients and increasing support and funding given by the government.

Diabetic retinopathy is considered a severe sight-threatening problem that results due to chronic diabetes. The treatment for diabetic retinopathy may require intraocular injections, anti-VEGF drugs, laser surgery, or vitrectomy, depending on the severity of the condition.

The rapidly expanding diabetic population coupled with increasing awareness of diabetic retinopathy is expected to drive the global diabetic retinopathy drug market in the coming years. In addition, rising medical procedures due to the high penetration of medical insurance and increasing government initiatives to prevent diabetes-related risks is also believed to garner the growth of the retinopathy drug market in the future.

This research report on the APAC diabetic retinopathy market has been segmented and sub-segmented into the following categories:

By Treatment Type:

  • Anti-Vascular Endothelial Growth Factor (VEGF) drug
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy     

By Indication:

  • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Mild
    • Moderate
    • Severe
  • Proliferative Diabetic Retinopathy (PDR) 

By End-User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Asia Pacific diabetic retinopathy market is expected to register the highest CAGR among all the regions in the global market during the forecast period and is mainly driven by the low-income population, lack of skilled professionals, and poor access to healthcare facilities. Emerging economies such as Japan and China are expected to boost the APAC market to achieve the new growth heights during the forecast period due to their growth in disposable income, rise in the aging population, increasing funding for diabetes research, diagnostic innovations, and large target populations. The Chinese diabetic retinopathy market is anticipated to achieve rapid growth during the forecast period. The Japanese diabetic retinopathy market is the largest in Asia-Pacific due to high medical costs and increasing disposable income. Also, increased use of Lucentis is foreseen to drive market growth in the area.


A few prominent companies in the APAC Diabetic Retinopathy Market profiled in the report are Bayer AG, Pfizer Inc., Hoffmann-La Roche Ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc., and Ampio Pharmaceuticals Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample